<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4512972</article-id><article-id pub-id-type="publisher-id">36</article-id><article-id pub-id-type="doi">10.1186/s40635-014-0036-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Calcium desensitisation in late polymicrobial sepsis is associated with loss of vasopressor sensitivity in a murine model</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Reddi</surname><given-names>Benjamin AJ</given-names></name><address><email>benjamin.reddi@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Beltrame</surname><given-names>John F</given-names></name><address><email>john.beltrame@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Richard L</given-names></name><address><email>richard.young@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>David P</given-names></name><address><email>david.p.wilson@adelaide.edu.au</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Intensive Care Unit, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000 Australia </aff><aff id="Aff2"><label/>Molecular Physiology of Vascular Function Laboratory, School of Medical Sciences, University of Adelaide, Frome Road, Adelaide, South Australia 5000 Australia </aff><aff id="Aff3"><label/>Discipline of Medicine, University of Adelaide, Frome Road, Adelaide, South Australia 5000 Australia </aff><aff id="Aff4"><label/>Basil Hetzel Institute, Queen Elizabeth Hospital, Woodville Road, Woodville, South Australia 5011 Australia </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#169; Reddi et al.; licensee Springer. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Sepsis is characterised by diminished vasopressor responsiveness. Vasoconstriction depends upon a balance: Ca<sup>2+</sup>-dependent myosin light-chain kinase promotes and Ca<sup>2+</sup>-independent myosin light-chain phosphatase (MLCP) opposes vascular smooth muscle contraction. The enzyme Rho kinase (ROK) inhibits MLCP, favouring vasoconstriction. We tested the hypothesis that ROK-dependent MLCP inhibition was attenuated in late sepsis and associated with reduced contractile responses to certain vasopressor agents.</p></sec><sec><title>Methods</title><p>This is a prospective, controlled animal study. Sixteen-week-old C57/BL6 mice received laparotomy or laparotomy with caecal ligation and puncture (CLP). Antibiotics, fluids and analgesia were provided before sacrifice on day 5. Vasoconstriction of the femoral arteries to a range of stimuli was assessed using myography: (i) depolarisation with 87 mM K<sup>+</sup> assessed voltage-gated Ca<sup>2+</sup> channels (L-type, Ca<sub>v</sub>1.2 Ca<sup>2+</sup> channels (LTCC)), (ii) thromboxane A<sub>2</sub> receptor activation assessed the activation state of the LTCC and ROK/MLCP axis, (iii) direct PKC activation (phorbol-dibutyrate (PDBu), 5 &#956;M) assessed the PKC/CPI-17 axis independent of Ca<sup>2+</sup> entry and (iv) &#945;<sub>1</sub>-adrenoceptor stimulation with phenylephrine (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) and noradrenaline (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) assessed the sum of these pathways plus the role of the sarcoplasmic reticulum (SR). ROK-dependent MLCP activity was indexed by Western blot analysis of P[Thr855]MYPT. Parametric and non-parametric data were analysed using unpaired Student's <italic>t</italic>-tests and Mann-Whitney tests, respectively.</p></sec><sec><title>Results</title><p>ROK-dependent inhibition of MLCP activity was attenuated in both unstimulated (<italic>n</italic> = 6 to 7) and stimulated (<italic>n</italic> = 8 to 12) vessels from mice that had undergone CLP (<italic>p</italic> &lt; 0.05). Vessels from CLP mice demonstrated reduced vasoconstriction to K<sup>+</sup>, thromboxane A<sub>2</sub> receptor activation and PKC activation (<italic>n</italic> = 8 to 13; <italic>p</italic> &lt; 0.05). &#945;<sub>1</sub>-adrenergic responses were unchanged (<italic>n</italic> = 7 to 12).</p></sec><sec><title>Conclusions</title><p>In a murine model of sepsis, ROK-dependent inhibition of MLCP activity in vessels from septic mice was reduced. Responses to K<sup>+</sup> depolarisation, thromboxane A<sub>2</sub> receptor activation and PKC activation were diminished <italic>in vitro</italic> whilst &#945;<sub>1</sub>-adrenergic responses remained intact. Inhibiting MLCP may present a novel therapeutic target to manage sepsis-induced vascular dysfunction.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vascular tone</kwd><kwd>Sensitisation</kwd><kwd>Noradrenaline</kwd><kwd>Shock</kwd><kwd>Rho kinase</kwd><kwd>Myosin light-chain phosphatase</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Septic shock arises when infection causes direct tissue injury and a maladaptive host response culminating in refractory vasodilation and loss of vasopressor sensitivity. Clinically, this manifests as septic shock and multi-organ failure, which even in modern intensive care units heralds a 90-day mortality rate of over 30% [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Vascular smooth muscle (VSM) contraction is determined by the balance of two opposing enzymatic processes: (i) myosin light-chain kinase (MLCK) phosphorylation of myosin enables actin-myosin cross bridge cycling and contraction; (ii) myosin light-chain phosphatase (MLCP) dephosphorylation of myosin uncouples actin-myosin, favouring relaxation. Activation of MLCK depends on cytosolic calcium (Ca<sup>2+</sup>) binding to calmodulin. Cystosolic Ca<sup>2+</sup> is derived from either the sarcoplasmic reticulum (SR) or the extracellular space through, for example, voltage-gated L-type Ca<sub>v</sub>1.2 Ca<sup>2+</sup> channels (LTCC). Vasoconstrictors variably modulate the cytosolic [Ca<sup>2+</sup>] and the degree of inhibition of MLCP to regulate vascular tone. MLCP can be inhibited either by (i) RhoA activation of Rho kinase (ROK), which inhibits MLCP by phosphorylating Thr855 of the MYPT regulatory subunit of MLCP [<xref ref-type="bibr" rid="CR3">3</xref>-<xref ref-type="bibr" rid="CR5">5</xref>], or (ii) PKC-mediated phosphorylation of Thr38 CPI-17, which directly inhibits MLCP [<xref ref-type="bibr" rid="CR6">6</xref>-<xref ref-type="bibr" rid="CR8">8</xref>]. Inhibiting MLCP promotes VSM contraction independent of the prevailing intracellular [Ca<sup>2+</sup>] - &#8216;Ca<sup>2+</sup> sensitisation&#8217;. On the other hand, increasing MLCP activity by reducing Thr855 phosphorylation of MYPT or reduced Thr38 CPI-17 phosphorylation shifts the [Ca<sup>2+</sup>]:force relationship to the right - effectively reducing Ca<sup>2+</sup> sensitivity. Individual vasopressors vasoconstrict through different signalling pathways; for instance, thromboxane is bimodal, activating LTCC and RhoA/ROK [<xref ref-type="bibr" rid="CR3">3</xref>], whilst &#945;<sub>1</sub>-adrenergic receptor agonists are multimodal, inducing vasoconstriction through two sources of Ca<sup>2+</sup> (SR and LTCC) and two MLCP inhibitory pathways (RhoA/ROK and PKC/CPI-17) [<xref ref-type="bibr" rid="CR9">9</xref>]. A figure summarising these contractile signalling pathways is provided (Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p><bold>Smooth muscle cell contraction depends on Ca</bold>
<sup><bold>2+</bold></sup>
<bold>-dependent and Ca</bold>
<sup><bold>2+</bold></sup>
<bold>-independent pathways.</bold> Actin-myosin cross bridge cycling and smooth muscle contraction depend on phosphorylation of the myosin light chain by Ca<sup>2+</sup>: calmodulin (CaM)-dependent myosin light-chain kinase (MLCK). Relaxation is favoured by myosin light-chain phosphatase (MLCP) as the active subunit removes the phosphoryl group from the myosin light chain. Cytosolic [Ca<sup>2+</sup>] is derived from (i) the extracellular space (through voltage-operated Ca<sup>2+</sup> channels (VOCC; predominantly Ca<sub>v</sub>1.2 L-type Ca<sup>2+</sup> channels) and receptor-operated non-specific cation channels (ROCC)) or (ii) IP<sub>3</sub>-dependent release from the sarcoplasmic reticulum (SR). MLCP is inhibited, favouring contraction, either through (i) direct inhibition by PKC-dependent CPI-17 or (ii) inhibitory phosphorylation of the regulatory subunit MYPT by RhoA-dependent Rho kinase. &#945;<sub>1</sub>-adrenergic G protein-coupled receptors (GPCR) activate all four contractile pathways: VOCC/ROCC, IP<sub>3</sub>/SR, PKC/CPI-17 and RhoA/ROK; TxA<sub>2</sub> GPCR activate VOCC and RhoA/ROK; PDBu activates PKC/CPI-17 whilst high-[K<sup>+</sup>]-mediated depolarisation activates VOCC. PLC, phospholipase C; PIP<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; DAG, diacylglycerol; IP<sub>3</sub>, inositol triphosphate.</p></caption><graphic xlink:href="40635_2014_36_Fig1_HTML" id="MO1"/></fig></p><p>There is evidence that Ca<sup>2+</sup> desensitisation contributes to septic shock: in a rat model, acute endotoxaemia was associated with augmented MLCP activity and reduced sensitivity to an &#945;<sub>1</sub>-adrenergic agonist [<xref ref-type="bibr" rid="CR10">10</xref>]. Other models of sepsis have identified a rightward shift in the cytosolic [Ca<sup>2+</sup>]: force relationship [<xref ref-type="bibr" rid="CR11">11</xref>] and attenuated vasopressor responses despite the presence of augmented cytosolic [Ca<sup>2+</sup>] [<xref ref-type="bibr" rid="CR12">12</xref>], suggesting increased activity of MLCP. Many investigations into the vascular pathology of septic shock have focused on the early, hyperdynamic phase of sepsis. Importantly, however, 70% of deaths from sepsis occur after the first 3 days [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]. Mechanisms of vascular dysfunction at this later stage of disease remain relatively unexplored, but important differences have been identified; specifically, whilst early sepsis is associated with impaired vascular responses to &#945;<sub>1</sub>-adrenergic agonists <italic>in vitro</italic> and a reduction in cytosolic Ca<sup>2+</sup> entry, in the later phases of sepsis, the <italic>in vitro</italic> response to &#945;<sub>1</sub>-adrenergic agonists and Ca<sup>2+</sup> flux are restored [<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref>], as is the <italic>in vivo</italic> blood pressure response to moderate doses of phenylephrine [<xref ref-type="bibr" rid="CR17">17</xref>]. However, sensitivity to local vasoconstriction by thromboxane A<sub>2</sub> (TxA<sub>2</sub>) and direct electrical coupling of the VSM membrane, significant for their importance in regulating regional blood flow [<xref ref-type="bibr" rid="CR18">18</xref>], has not been evaluated in sepsis. Unlike &#945;<sub>1</sub>-adrenergic agonists, TxA<sub>2</sub> and membrane depolarisation do not stimulate SR Ca<sup>2+</sup> release or PKC/CPI-17-mediated inhibition of MLCP and are therefore potentially more vulnerable to attenuation of the RhoA/ROK pathway [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR19">19</xref>]. Diminished efficacy of endogenous TxA<sub>2</sub> and direct depolarisation secondary to dysfunction of the RhoA/ROK pathway may contribute to systemic hypotension in septic shock and dysregulation of regional blood flow [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>To address this gap in knowledge, we used a murine caecal ligation and puncture (CLP) model of sepsis that included an intensive care treatment regimen that simulated the clinical experience of a septic patient [<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref>]. CLP is a well-described, reproducible model of sepsis incorporating polymicrobial infection and tissue necrosis [<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref>]. As an animal model, it replicates many of the physiological, haemodynamic and metabolic sequelae of sepsis [<xref ref-type="bibr" rid="CR25">25</xref>-<xref ref-type="bibr" rid="CR28">28</xref>]. We used a 5-day model of sepsis to identify mechanisms that contribute to vasopressor insensitivity during the late stages of sepsis, noting that most deaths from sepsis occur after the first 3 days [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]. We hypothesised that CLP sepsis would be associated with increased MLCP activity and Ca<sup>2+</sup> desensitisation and that this activity would be associated with a reduction in <italic>in vitro</italic> vascular responses to vasoconstrictors such as thromboxane A<sub>2</sub>, phorbol ester and high K<sup>+</sup> which are uni- or bimodal, engaging one or two signalling pathways. We hypothesised that responses to &#945;<sub>1</sub>-adrenergic agonists which invoke multimodal mechanisms of Ca<sup>2+</sup> entry (LTCC and SR Ca<sup>2+</sup>) and Ca<sup>2+</sup> sensitisation (PKC/CPI-17 and Rho/ROK) would be relatively preserved <italic>in vitro</italic>.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Mice</title><p>All animal procedures were approved by the Animal Ethics Committees of the Institute of Medical and Veterinary Science (IMVS; Adelaide, South Australia) and the University of Adelaide (Adelaide, South Australia). Twenty-six, 16-week-old, male C57/BL6 mice purchased from the Animal Resources Centre, WA, were housed in the IMVS Animal Care Facility in individual cages following surgery with food and water <italic>ad libitum</italic>. Changes in clinical status were determined by cumulative clinical record scores as outlined previously [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec4"><title>Caecal ligation and puncture</title><p>Sixteen mice underwent a midline laparotomy under general anaesthetic (1% to 1.5% isoflurane in oxygen) followed by location and ligation of the caecum 5 mm from the ileocaecal valve. A 21-gauge needle was used to puncture the caecum midway between the ligature and the tip of the caecum. Faecal material was expressed from the caecum into the abdominal cavity through the puncture site before the perforated caecum was placed back into the abdominal cavity and the incision was sutured. Morbidity associated with CLP surgery was assessed by monitoring for weight loss, abnormal temperatures (normal core temperature range 34 to 37) and other morbidity indicators including ruffled coat, hunched posture, reduced mobility, diarrhoea, abdominal distention, loss of righting ability and laboured respiration; these parameters were scored to calculate a cumulative disease index [<xref ref-type="bibr" rid="CR25">25</xref>]. <italic>Post</italic>-<italic>mortem</italic> was carried out on representative CLP mice demonstrating acute suppurative and necrotising peritonitis. Ten mice underwent laparotomy without CLP as sham controls. All mice underwent an intensive care regime post-surgery: twice-daily subcutaneous administration of antibiotic (Baytril (enrofloxacin), 0.03 mg kg<sup>&#8722;1</sup>, 50 &#956;l), fluid (saline 1 ml) for 5 days and analgesia (butorphanol, 0.05 mg kg<sup>&#8722;1</sup>, 25 &#956;l) for 2 days. On day 5, surviving mice were killed with pentobarbitone (60 mg kg<sup>&#8722;1</sup> i.p.) before tissue collection.</p></sec><sec id="Sec5"><title>Isolation of vessels</title><p>Femoral and caudal arteries were placed in cold Ca<sup>2+</sup>-free normal HEPES-Tyrode buffer containing, in mM, 135.5 NaCl, 5.9 KCl, 1.2 MgCl<sub>2</sub>, 11.6 glucose and 11.6 HEPES, pH 7.4, dissected free of adventitia and cut into 2-mm segments; femoral and caudal arteries were 250 and 300 &#956;m in diameter, respectively. Caudal artery segments from sham and CLP treatment groups were snap-frozen in liquid nitrogen and stored at &#8722;80&#176;C prior to SDS-PAGE/Western blot analysis.</p></sec><sec id="Sec6"><title>Vascular myography</title><p>Femoral arterial segments from sham and CLP treatment groups were mounted on a DMT 610M wire myograph (DMT, Aarhus, Denmark) to quantify isometric tension following stimulation. Following length tension analysis, femoral arteries were set at an optimal resting tension of 3 mN and equilibrated in normal HEPES-Tyrode buffer (in mM, 135.5 NaCl, 5.9 KCl, 1.2 MgCl<sub>2</sub>, 2.5 CaCl<sub>2</sub>, 11.6 glucose, 11.6 HEPES, pH 7.4). The arteries were equilibrated for 30 min before being stimulated three times with a depolarising stimulus of 87 mM K<sup>+</sup>-HEPES-Tyrode buffer (K<sup>+</sup>HT), in which NaCl was substituted with KCl to maintain an iso-osmolar solution. Following relaxation in NHT buffer, the arteries were incubated with the stable thromboxane A<sub>2</sub> receptor agonist U46619 (0.1 &#956;M), the direct PKC activator phorbol-dibutyrate (PDBu) (5 &#956;M), the &#945;<sub>1</sub>-adrenergic agonist phenylephrine (PE) (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) or noradrenaline (NA) (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M), primarily an &#945;<sub>1</sub>-adrenergic agonist but with significant &#946;-adrenergic agonist action. Noradrenaline was used because, although less specific in action than phenylephrine, it is more commonly used both in sepsis research and clinical practice.</p><p>Following a 10-min stimulation with U46619 (0.1 &#956;M) or PDBu (5 &#956;M) or generation of a dose-response relationship with NA or PE (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M), tissues were snap-frozen in dry ice-cold 10% trichloroacetic acid/acetone, washed with dry ice-cold acetone and stored at &#8722;80&#176;C prior to SDS-PAGE/Western blot analysis.</p><p>Myography data and biochemical analysis of stimulated arterial tissue was derived from the femoral artery. As quantities of the femoral artery were limited, biochemical analysis of unstimulated sham and CLP tissue was derived from the caudal artery (nb caudal segments were always compared with caudal and femoral with femoral). Endothelial integrity of arterial segments was confirmed by phenylephrine challenge followed by an intact 90% ACh relaxation.</p></sec><sec id="Sec7"><title>Western blot analysis of MYPT</title><p>For analysis of total MYPT and P[Thr855]MYPT, proteins were extracted from each 2-mm arterial segment using 100 &#956;l of sample buffer containing 50 mM Tris-HCl, pH 6.8, 1% (<italic>w</italic>/<italic>v</italic>) SDS, 1&#215; Complete&#8482; protease inhibitor cocktail (Roche, Mannheim, Germany), 100 &#956;M di-isopropylfluorophosphate (Sigma-Aldrich, Caste Hill, Australia), 10 mM DTT, 10% (<italic>w</italic>/<italic>v</italic>) sucrose and 0.1% (<italic>w</italic>/<italic>v</italic>) bromophenol blue. Samples were heated to 95&#176;C for 5 min and then agitated for 30 min prior to SDS-PAGE using a Bio-Rad (Sydney, Australia) Mini-PROTEAN II unit at 200 V for 60 min. For analysis of MYPT, proteins were transferred, using a Bio-Rad Mini transfer unit, onto 0.22 &#956;m nitrocellulose (Bio-Rad) at 100 V for 30 min in transfer buffer containing 25 mM Tris-HCl, 192 mM glycine, 0.1% (<italic>w</italic>/<italic>v</italic>) SDS and 20% (<italic>v</italic>/<italic>v</italic>) methanol.</p><p>Following protein transfer to nitrocellulose, non-specific binding sites were blocked with 50% LI-COR Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) for 60 min, followed by incubation with TBS-T (20 mM Tris, 150 mM NaCl, 0.05% (<italic>v</italic>/<italic>v</italic>) Tween-20) containing either a mouse-derived affinity-purified anti-MYPT antibody (1:1,000) made in-house or a commercially available (Upstate Biotechnology, Lake Placid, NY, USA) rabbit-derived anti-P[Thr855]MYPT antibody (1:1,000) for 60 min. Nitrocellulose membranes were washed three times in TBS-T and incubated with a 1:10,000 dilution (in TBS-T) of biotin-conjugated secondary antibodies (Pierce Thermo Scientific, Rockford, IL, USA): anti-mouse IgG for MYPT and anti-rabbit IgG for P[Thr855]MYPT (1:10,000), for 60 min before another three washes with TBS-T. The nitrocellulose was then incubated for 60 min in TBS-T with a 1:10,000 dilution of streptavidin conjugated to the 800-nm DyLight fluorochome (Pierce Thermo Scientific); fluorescence was detected and quantified using the LI-COR Odyssey system. Western blot signals of the Thr855 phosphorylation state of MYPT of untreated vs. U46619 (0.1 &#956;M)- or PDBu (5 &#956;M)-treated rat caudal artery as previously published [<xref ref-type="bibr" rid="CR3">3</xref>] were used as controls.</p><p>Although consistency of protein content was confirmed with Coomassie blue-stained actin, all Western blot signals were evaluated and found to be within the linear range of detection. Vessel size and protein load were not significantly different; nevertheless, the primary outcome of phosphorylation analysis is expressed as a ratio of P[Thr855]MYPT to total MYPT taken from the same sample.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The Mann-Whitney test was used for non-parametric data comparisons, and Student's <italic>t</italic>-test was used to compare parametric data (both two-tailed); <italic>p</italic> &lt; 0.05 was considered statistically significant. Asterisks indicate statistically significant differences from control; data are presented as mean &#177; SEM.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Morbidity and mortality</title><p>There were no deaths in sham-operated mice. The mortality rate in CLP-operated mice was 16%, similar to the real-world experience of severe sepsis managed in a critical care environment [<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref>]. The cumulative disease index was significantly higher for mice undergoing CLP surgery than for sham-operated controls (<italic>p</italic> &lt; 0.05, data not shown) [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec11"><title>Does the ROK-dependent basal activity state of myosin phosphatase, indexed by Thr855 MYPT phosphorylation, differ between septic and control mice?</title><p>To compare the basal activity state of MLCP in sham and CLP mice, the proportion of total MYPT in the [Thr855]-phosphorylated, i.e. ROK-inhibited, state was identified using Western blot analysis of unstimulated mouse caudal artery segments. The proportion of [Thr855]-phosphorylated MYPT in unstimulated vessels was greater in sham than in CLP mice (<italic>n</italic> = 6 to 7; <italic>p</italic> &lt; 0.05), indicating that MLCP was more active in CLP mice favouring vasorelaxation (Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Sepsis was associated with increased activation state of MLCP.</bold> The activity state of MLCP was greater in isolated, unstimulated caudal arteries from 5-day CLP mice than in those from sham mice. The increased activity state of MLCP was indexed by reduction in the ratio of Thr855 phosphorylated to unphosphorylated MYPT determined by Western blot analysis of snap-frozen vessel segments. *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 6 to 7.</p></caption><graphic xlink:href="40635_2014_36_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Does the ability of thromboxane A<sub>2</sub> receptor stimulation to inhibit MLCP differ in CLP and sham mice?</title><p>Thromboxane activates the RhoA/ROK pathway leading to inhibitory phosphorylation of Thr855 MYPT, the regulatory subunit of MLCP, favouring contraction by Ca<sup>2+</sup> sensitisation [<xref ref-type="bibr" rid="CR3">3</xref>]. To establish whether the ability of the TxA<sub>2</sub> receptor to inhibit MLCP was attenuated in CLP compared to sham mice, the [Thr855] phosphorylation state of MYPT was compared in isolated femoral artery segments following challenge with the TxA<sub>2</sub> receptor agonist U46619 (0.1 &#956;M). CLP mice showed reduced phosphorylation of [Thr855]MYPT (less MLCP inhibition) in response to TxA<sub>2</sub> receptor stimulation than sham-treated mice (Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>; <italic>n</italic> = 9 to 12; <italic>p</italic> &lt; 0.05).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>TxA</bold>
<sub><bold>2</bold></sub>
<bold>receptor-mediated inhibition of MLCP was attenuated in sepsis.</bold> The activity state of MLCP was increased in femoral arteries stimulated with U46619 (0.1 &#956;M) in 5-day CLP mice relative to those in sham mice (indexed by reduction in the ratio of Thr855 phosphorylated to unphosphorylated MYPT on Western blot analysis). *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 9 to 12.</p></caption><graphic xlink:href="40635_2014_36_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Was the reduction in Thr855 MLCP phosphorylation in CLP mice associated with a reduction in vascular contractility?</title><p>TxA<sub>2</sub> elicits VSM contraction both through Rho kinase-mediated MLCP inhibition and by increasing the open probability of LTCC. If RhoA/ROK activity was disrupted during sepsis, decreasing [Thr855]MYPT phosphorylation, it would be expected that activation of TxA<sub>2</sub> receptors would fail to fully restore MLCP inhibition. The consequence would be reduced Ca<sup>2+</sup> sensitivity and a diminished contractile response to the TxA<sub>2</sub> mimetic U46619. The contraction of isolated femoral artery segments in response to U46619 (0.1 &#956;M) was attenuated in CLP compared to sham mice (Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref>; <italic>n</italic> = 10 to 12; <italic>p</italic> &lt; 0.05), consistent with the hypothesis that reduced MLCP inhibition contributes to septic shock.<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>The vascular contractile response to the thromboxane receptor agonist U46619 was attenuated in sepsis.</bold> Wire myograph-mounted femoral arteries from 5-day CLP mice developed lower tension under stimulation with U46619 (0.1 &#956;M) compared to those from sham mice. *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 10 to 12.</p></caption><graphic xlink:href="40635_2014_36_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>Was the contractile response to PDBu, a direct activator of PKC/CPI-17, attenuated in sepsis?</title><p>The direct PKC agonist PDBu inhibits MLCP by stimulating PKC-dependent phosphorylation of Thr38 of CPI-17 [<xref ref-type="bibr" rid="CR31">31</xref>]. In the Thr38-phosphorylated state, CPI-17 is a specific, direct inhibitor of MLCP [<xref ref-type="bibr" rid="CR6">6</xref>]. Contractile responses to PDBu (5 &#956;M) were reduced in femoral artery segments from CLP mice compared with segments from sham mice (Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref>; <italic>n</italic> = 8; <italic>p</italic> &lt; 0.05). As expected, treatment of artery segments from control mice with PDBu did not directly alter the Thr855 phosphorylation of MYPT (data not shown) [<xref ref-type="bibr" rid="CR19">19</xref>]. To identify whether the attenuated contractile response to PDBu in CLP mice may have resulted from a sepsis-dependent reduction in baseline Thr855 phosphorylation of MYPT and consequently augmented MLCP activity, we used Western blot analysis to ascertain the Thr855 phosphorylation state of MYPT in control and CLP mice. We identified a reduction in Thr855 phosphorylation of MYPT in the PDBu (5 &#956;M)-treated femoral artery segments from CLP mice compared to segments from sham mice (Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref>; <italic>n</italic> = 8; <italic>p</italic> &lt; 0.05).<fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>The vascular contractile response to the direct PKC activator phorbol-dibutyrate (PDBu) was attenuated in sepsis.</bold> Wire myograph-mounted femoral arteries from 5-day CLP mice developed lower tension under stimulation with PDBu (5 &#956;M) compared to those from sham mice. *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 8 to 13.</p></caption><graphic xlink:href="40635_2014_36_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>Attenuated PKC-dependent contraction in septic mouse artery was associated with reduced inhibitory phosphorylation of MLCP.</bold> The activity state of MLCP was increased in femoral arteries stimulated with PDBu (5 &#956;M) in 5-day CLP mice relative to those in sham mice (indexed by reduction in the ratio of Thr855 phosphorylated to unphosphorylated MYPT on Western blot analysis). *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 8.</p></caption><graphic xlink:href="40635_2014_36_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec15"><title>Could the attenuated contractile response to TxA<sub>2</sub> receptor and PKC/CPI-17 stimulation in CLP mice be wholly explained by changes in membrane potential during sepsis?</title><p>A significant body of work has demonstrated that augmented ATP-sensitive potassium (K<sub>ATP</sub>) channel function causes VSM hyperpolarisation with consequent vasodilation and vasopressor resistance in sepsis [<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>]. Contractile responses to U46619 and PKC/CPI-17 depend on both the basal activity of MLCP and baseline conductance of the K<sub>ATP</sub> channel as it modulates membrane potential and hence the activity of LTCC. In order to isolate the contributions made by increased MLCP and K<sub>ATP</sub> channel activities to attenuated functional vascular contractile responses, we made use of a high-K<sup>+</sup> depolarising solution, which directly activates LTCC independent of K<sub>ATP</sub> channel conductance. The contractile response to high-K<sup>+</sup>-mediated depolarisation of isolated femoral artery segments from CLP mice was reduced compared to those from sham mice independent of K<sub>ATP</sub> activity (Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref>; <italic>n</italic> = 9 to 13; <italic>p</italic> &lt; 0.05).<fig id="Fig7"><label>Figure 7</label><caption><p>
<bold>The vascular contractile response to depolarisation with high-K</bold>
<sup><bold>+</bold></sup>
<bold>HT solution was attenuated in sepsis.</bold> Wire myograph-mounted femoral arteries from 5-day CLP mice developed lower tension under stimulation with a depolarising high-K<sup>+</sup> HT solution compared to those from sham mice. *<italic>p</italic> &lt; 0.05, <italic>n</italic> = 9 to 13.</p></caption><graphic xlink:href="40635_2014_36_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec16"><title>Is the contractile response to &#945;<sub>1</sub>-adrenergic stimulation intact during the later phase of sepsis?</title><p>VSM stimulation by &#945;<sub>1</sub>-adrenergic agonists involves Ca<sup>2+</sup> entry through LTCC and from SR as well as Ca<sup>2+</sup> sensitisation mediated by both PKC/CPI-17 and RhoA/ROK activation [<xref ref-type="bibr" rid="CR9">9</xref>]. Contrary to acute endotoxaemia models, studies analysing vessels after longer periods of sepsis have found recovery of contractile responses to &#945;<sub>1</sub>-adrenergic stimulation [<xref ref-type="bibr" rid="CR16">16</xref>]. We used isolated femoral vessels from a 5-day model of polymicrobial sepsis, somewhat akin to a clinical scenario, to identify whether survivors had recovered &#945;<sub>1</sub>-adrenergic response. Figure&#160;<xref rid="Fig8" ref-type="fig">8</xref> shows that the contractile response to the &#945;<sub>1</sub>-adrenergic agonists noradrenaline (Figure&#160;<xref rid="Fig8" ref-type="fig">8A</xref>) and phenylephrine (Figure&#160;<xref rid="Fig8" ref-type="fig">8B</xref>) (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) was not significantly different in CLP compared to sham mice (<italic>E</italic><sub>max</sub> and EC<sub>50</sub><italic>p</italic> = NS, <italic>n</italic> = 7 to 12).<fig id="Fig8"><label>Figure 8</label><caption><p>
<bold>Vasoconstrictor responses to stimulation with phenylephrine and noradrenaline remained intact in arteries from septic mice.</bold> Dose-response curves to stimulation with NA (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) <bold>(A)</bold> and PE (10<sup>&#8722;8</sup> to 10<sup>&#8722;4</sup> M) <bold>(B)</bold> were generated using wire myograph-mounted femoral arteries. For both agonists, dose-response curves in 5-day CLP mice (filled circles) and sham mice (hollow circles) did not differ with regard to EC<sub>50</sub> or <italic>E</italic>
<sub>max</sub> (<italic>p</italic> &gt; 0.05). (<italic>n</italic> = 7 to 12).</p></caption><graphic xlink:href="40635_2014_36_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p>Hospital mortality from septic shock remains around 30%, highlighting the need for a more complete understanding of the mechanisms of pathological vasodilation [<xref ref-type="bibr" rid="CR1">1</xref>]. Proposed mechanisms include reduced &#945;<sub>1</sub>-receptor density and reduced &#945;<sub>1</sub>-adrenergic signal transduction [<xref ref-type="bibr" rid="CR34">34</xref>], activation of vascular K<sub>ATP</sub> channels [<xref ref-type="bibr" rid="CR33">33</xref>], impaired SR Ca<sup>2+</sup> release [<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR35">35</xref>], relative corticosteroid and vasopressin deficiency [<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref>] and activation of inducible nitric oxide synthase [<xref ref-type="bibr" rid="CR38">38</xref>] and vasodilating inflammatory mediators [<xref ref-type="bibr" rid="CR39">39</xref>-<xref ref-type="bibr" rid="CR42">42</xref>]. We tested the hypothesis that reduced inhibition of MLCP promotes Ca<sup>2+</sup> desensitisation, contributing to pathological vasodilation in a murine CLP model of sepsis. Normally, MLCP inhibition sensitises the vascular contractile apparatus to Ca<sup>2+</sup>, favouring vasoconstriction [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR43">43</xref>]. Events that release MLCP inhibition by reducing either (i) RhoA/ROK-mediated inhibitory Thr855 phosphorylation of the regulatory subunit MYPT or (ii) PKC-mediated Thr38 phosphorylation of CPI-17 favour vasorelaxation [<xref ref-type="bibr" rid="CR19">19</xref>]. Using a 5-day murine model of polymicrobial sepsis, we identified that both the baseline phosphorylation state of Thr855 MYPT and the Thr855 phosphorylation state of MYPT following stimulation with the TxA<sub>2</sub> receptor agonist U46619 (0.1 &#956;M) were attenuated in septic animals compared to sham-operated controls (Figures&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). Reduced Thr855 MYPT phosphorylation was associated with reduced vasoconstrictor response to U46619, PDBu or high-[K<sup>+</sup>]-mediated depolarisation (Figures&#160;<xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig7" ref-type="fig">7</xref>). These data are consistent with late sepsis being associated with Ca<sup>2+</sup> desensitisation, rendering the vasculature less responsive to certain endogenous vasopressors.</p><p>Previous data are consistent with the view that vasopressor responses can be attenuated in sepsis due to Ca<sup>2+</sup> desensitisation, rather than as a consequence of reduced flux of Ca<sup>2+</sup> into the cytosol [Ca<sup>2+</sup>]<sub>cyt</sub>. For example, the [Ca<sup>2+</sup>]<sub>cyt</sub> content in the aortae of rats with confirmed CLP sepsis was actually elevated relative to that of non-septic animals [<xref ref-type="bibr" rid="CR12">12</xref>]. Isolated mesenteric arteries from rats injected with <italic>Escherichia coli</italic> lipopolysaccharide (LPS) also had elevated VSM [Ca<sup>2+</sup>]<sub>cyt</sub> and a force:intracellular Ca<sup>2+</sup> relationship shifted to the right, consistent with Ca<sup>2+</sup> desensitisation [<xref ref-type="bibr" rid="CR11">11</xref>]. More recently, in an acute (6 to 24 h) rat model of LPS-induced endotoxaemia, da Silva-Santos and colleagues identified reduced inhibitory phosphorylation of MLCP in the mesenteric vasculature, associated with reduced vasopressor sensitivity [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Sepsis in humans typically lasts longer than most experimental animal models of sepsis, which, for practical reasons, are often less than 24 h. In clinical practice, most deaths occur after several days of sepsis [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]. It is arguable that a CLP model, whereby tissue necrosis and polymicrobial infection with host enteric organisms develop over several days after traumatic perforation of a viscus, reflects a more common clinical paradigm than sepsis induced by injection of bacterial inoculum or LPS [<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref>]. We evaluated the functional and molecular features of murine vascular dysfunction 5-days post caecal ligation and puncture.</p><p>Our data identified an important difference in vascular response between acute endotoxaemia and a 5-day peritonitis model: the first 2 to 6 h of acute endotoxaemia models typically demonstrate reduced vasoconstriction in response to &#945;<sub>1</sub>-adrenoceptor stimulation [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR46">46</xref>]. In contrast, after 5 days of polymicrobial sepsis, we identified normal <italic>in vitro</italic> &#945;<sub>1</sub>-adrenoceptor-mediated vasoconstriction, consistent with endotoxaemia models, which found recovery of <italic>in vitro</italic> and <italic>in vivo</italic> sensitivity to moderate doses of &#945;<sub>1</sub>-adrenoceptor agonist between 6 and 24 h [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>]. However, our data identifies clear insensitivity to other vasoconstrictor mechanisms, including TxA<sub>2</sub> receptor activation and direct membrane depolarisation (Figures&#160;<xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig7" ref-type="fig">7</xref>). &#945;<sub>1</sub>-adrenoceptor agonist responses may demonstrate resilience by recruiting multiple, parallel signalling pathways to achieve contraction (Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>), specifically 1) LTCC opening, 2) SR Ca<sup>2+</sup> release, 3) inhibition of MLCP by PKC/CPI-17 and 4) inhibition of MLCP by RhoA/ROK phosphorylation of MYPT. In particular, &#945;<sub>1</sub>-adrenoceptor agonists increase cytosolic [Ca<sup>2+</sup>]<sub>cyt</sub> through SR Ca<sup>2+</sup> release, a mechanism not shared by TxA<sub>2</sub> receptor, PDBu activation or high-K<sup>+</sup>-mediated contraction [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR19">19</xref>], and have two mechanisms by which to inhibit MLCP through both PKC/CPI-17 and RhoA/ROK. These data provide a mechanistic explanation for the effectiveness of &#945;<sub>1</sub>-adrenoceptor agonists as vasoconstrictors in sepsis.</p><p>The results of our study together with those of da Silva-Santos and colleagues [<xref ref-type="bibr" rid="CR10">10</xref>] indicate two salient findings: 1) disinhibition of MLCP favouring Ca<sup>2+</sup> desensitisation has been identified at different time points and in different models of sepsis, suggesting a potentially important role in the pathogenesis of septic shock, and 2) preservation of <italic>in vitro</italic> &#945;<sub>1</sub>-adrenoceptor agonist sensitivity may not necessarily reflect intact vasoconstrictor responses to other physiologically significant stimuli.</p><p>Several potential mechanisms by which sepsis might promote MLCP disinhibition and Ca<sup>2+</sup> desensitisation can be postulated. Pathogenic bacteria produce toxins capable of directly interfering with RhoA/ROK-dependent phosphorylation of MYPT, thereby disinhibiting MLCP and opposing cell contraction [<xref ref-type="bibr" rid="CR19">19</xref>]: <italic>E. coli</italic> and <italic>Clostridium botulinum</italic> derived exotoxins EDIN and C3-transferase ADP-ribosylate and inactivate RhoA, <italic>Clostridium difficile</italic> toxin B glycosylates and inactivates RhoA whilst <italic>Yersinia</italic> spp. produces toxin Yop T which prevents RhoA from co-localising in the cell membrane with Rho kinase [<xref ref-type="bibr" rid="CR47">47</xref>-<xref ref-type="bibr" rid="CR49">49</xref>]. In contrast, SpA from <italic>Staphylococcus aureus</italic> and CNF1 from <italic>E. coli</italic> promote RhoA/ROK activity [<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref>]. Endogenous mediators might also contribute to Ca<sup>2+</sup> desensitisation: nitric oxide, kynurenine and ANP levels are elevated in septic shock [<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR52">52</xref>], potentially promoting protein kinase G (PKG)-dependent disinhibition of MLCP and Ca<sup>2+</sup> desensitisation [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref>].</p><p>Our findings of impaired response to TxA<sub>2</sub> and membrane depolarisation may be of particular clinical significance for two reasons: Firstly, it is well established that restoration of normal systemic circulatory parameters is not necessarily indicative of restored regional perfusion, and indeed, ongoing regional ischaemia despite restoration of systemic blood pressure is associated with poor clinical outcome [<xref ref-type="bibr" rid="CR55">55</xref>-<xref ref-type="bibr" rid="CR58">58</xref>]. Microvascular splanchnic perfusion is not only reduced but highly heterogeneous in septic shock even within areas of uniform metabolic demand [<xref ref-type="bibr" rid="CR20">20</xref>], indicating a failure of local vasomotor regulation. Since TxA<sub>2</sub> [<xref ref-type="bibr" rid="CR59">59</xref>] and local VSM membrane potential [<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref>] play a key role in local vasomotor regulation, our evidence that their effectiveness is impaired in late sepsis and might be restored by MLCP inhibition opens a potentially useful area of investigation. Secondly, the experimentally observed restoration of &#945;<sub>1</sub>-adrenergic responses <italic>in vitro</italic> may not be borne out in the septic patient because <italic>in vivo</italic> endogenous vasoconstrictors such as constitutively secreted TxA<sub>2</sub> and direct depolarisation potentiate the response to an &#945;<sub>1</sub>-adrenergic agonist [<xref ref-type="bibr" rid="CR62">62</xref>]. The apparently attenuated response to &#945;<sub>1</sub>-adrenergic agonists <italic>in vivo</italic> may reflect diminished response to these normally synergistic vasopressor pathways.</p><sec id="Sec18"><title>Implications for clinical research and management</title><p>Our data, from a murine model, identify the association between MLCP disinhibition and vasopressor insensitivity in a murine model of sepsis. Future studies relating MLCP activity and regional blood flow <italic>in vivo</italic> in large animals and ultimately human sepsis patients will provide valuable insights into the specific clinical consequences of myosin phosphatase dysregulation.</p><p>Advances in our understanding of the pathobiology of sepsis have characterised sepsis as a heterogeneous disease, and optimal therapy will need to be tailored to particular unique patient/pathogen disease phenotypes [<xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref>]. Our findings suggest that in certain patients, excessive MLCP activity could contribute to the pathogenesis of sepsis. Identifying these patients would allow targeted therapeutic inhibition of MLCP or use of vasopressors less dependent upon RhoA/ROK signalling. Restoring vascular tone by directly inhibiting MLCP circumvents receptor downregulation and avoids promoting injurious increases in cytosolic [Ca<sup>2+</sup>] [<xref ref-type="bibr" rid="CR12">12</xref>]. In addition, targeting MLCP-dependent Ca<sup>2+</sup> sensitisation could be particularly effective in re-establishing local responsiveness to TxA<sub>2</sub> and membrane depolarisation, thereby restoring regulation of regional perfusion [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>The role of RhoA/ROK-mediated inhibition of MLCP extends beyond vascular smooth muscle: thrombin, a key mediator of the cross-talk between coagulation and inflammation in sepsis has, been shown to inactivate MLCP and therefore contraction in a RhoA-dependent manner in human endothelial cells [<xref ref-type="bibr" rid="CR65">65</xref>]. Given the prominence of endothelial dysfunction in sepsis, investigating the role of MLCP disinhibition in the pathogenesis of increased endothelial permeability is a research priority.</p></sec><sec id="Sec19"><title>Study limitations</title><p>We studied an animal model of sepsis at a single time point, and translating our results to patients mandates caution. To reflect human sepsis as closely as possible, we used a CLP model, which has advantages over bacterial inoculum and lipopolysaccharide models [<xref ref-type="bibr" rid="CR45">45</xref>], incorporating fluid and antibiotic therapy to recreate haemodynamic and metabolic phases of treated human polymicrobial sepsis. Mortality in the intervention arm was 16%, comparable to mortality in human studies of severe sepsis, but approximately half the mortality rate found amongst patients with septic shock [<xref ref-type="bibr" rid="CR30">30</xref>]. In addition, to maintain consistency, we analysed vessels from sacrificed mice rather than mice dying of their sepsis. For these reasons, our data may be derived from somewhat healthier animals than typical patients with septic shock.</p></sec></sec><sec id="Sec20" sec-type="conclusion"><title>Conclusions</title><p>Mechanisms of pathological vasodilation and vasopressor resistance in septic shock are diverse. Our observations in a murine caecal ligation and puncture model are consistent with the hypothesis that during sepsis disinhibition of myosin phosphatase promotes insensitivity to certain physiologically important vasoconstrictor mechanisms, such as thromboxane A<sub>2</sub> and membrane depolarisation. Approaches aimed at directly inhibiting MLCP might prove to be an effective therapeutic strategy to counter the pathological vasodilatation of septic shock.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#8217; contributions</bold></p><p>BR participated in study design, myography and biochemical analysis, data analysis and manuscript preparation. JB participated in study design. RY developed and generated animal model and assisted in manuscript preparation. DW assisted with experimental design, myography and biochemical analysis, data analysis and manuscript preparation. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Keh</surname><given-names>D</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Freivogel</surname><given-names>K</given-names></name><name><surname>Weiss</surname><given-names>YG</given-names></name><name><surname>Benbenishty</surname><given-names>J</given-names></name><name><surname>Kalenka</surname><given-names>A</given-names></name><name><surname>Forst</surname><given-names>H</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name><name><surname>Cuthbertson</surname><given-names>BH</given-names></name><name><surname>Payen</surname><given-names>D</given-names></name><name><surname>Briegel</surname><given-names>J</given-names></name></person-group><article-title>Hydrocortisone therapy for patients with septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>2</issue><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa071366</pub-id><?supplied-pmid 18184957?><pub-id pub-id-type="pmid">18184957</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">The Pro CI (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683&#8211;1693</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Wilson DP, Susnjar M, Kiss E, Sutherland C, Walsh MP (2005) Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca<sup>2+</sup> entry and Ca<sup>2+</sup> sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J 389(Pt 3):763&#8211;774</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muranyi</surname><given-names>A</given-names></name><name><surname>Derkach</surname><given-names>D</given-names></name><name><surname>Erdodi</surname><given-names>F</given-names></name><name><surname>Kiss</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Hartshorne</surname><given-names>DJ</given-names></name></person-group><article-title>Phosphorylation of Thr695 and Thr850 on the myosin phosphatase target subunit: inhibitory effects and occurrence in A7r5 cells</article-title><source>FEBS Lett</source><year>2005</year><volume>579</volume><issue>29</issue><fpage>6611</fpage><lpage>6615</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2005.10.055</pub-id><?supplied-pmid 16297917?><pub-id pub-id-type="pmid">16297917</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Stevenson AS, Matthew JD, Eto M, Luo S, Somlyo AP, Somlyo AV (2004) Uncoupling of GPCR and RhoA-induced Ca<sup>2+</sup>-sensitization of chicken amnion smooth muscle lacking CPI-17. FEBS Lett 578(1&#8211;2):73&#8211;79</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Ohmori</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>F</given-names></name></person-group><article-title>A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C: isolation from porcine aorta media and characterization</article-title><source>J Biochem</source><year>1995</year><volume>118</volume><issue>6</issue><fpage>1104</fpage><lpage>1107</lpage><?supplied-pmid 8720121?><pub-id pub-id-type="pmid">8720121</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>M</given-names></name><name><surname>Kitazawa</surname><given-names>T</given-names></name><name><surname>Brautigan</surname><given-names>DL</given-names></name></person-group><article-title>Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><issue>24</issue><fpage>8888</fpage><lpage>8893</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307812101</pub-id><?supplied-pmid 15184667?><pub-id pub-id-type="pmid">15184667</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Senba</surname><given-names>S</given-names></name><name><surname>Yazawa</surname><given-names>M</given-names></name><name><surname>Brautigan</surname><given-names>DL</given-names></name><name><surname>Eto</surname><given-names>M</given-names></name></person-group><article-title>Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><issue>43</issue><fpage>39858</fpage><lpage>39863</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107302200</pub-id><?supplied-pmid 11517233?><pub-id pub-id-type="pmid">11517233</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Dimopoulos GJ, Semba S, Kitazawa K, Eto M, Kitazawa T (2007) Ca<sup>2+</sup>-dependent rapid Ca<sup>2+</sup> sensitization of contraction in arterial smooth muscle. Circ Res 100(1):121&#8211;129</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva-Santos</surname><given-names>JE</given-names></name><name><surname>Chiao</surname><given-names>CW</given-names></name><name><surname>Leite</surname><given-names>R</given-names></name><name><surname>Webb</surname><given-names>RC</given-names></name></person-group><article-title>The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><issue>5</issue><fpage>1716</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31819efb43</pub-id><?supplied-pmid 19325475?><pub-id pub-id-type="pmid">19325475</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>MC</given-names></name><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>Stoclet</surname><given-names>JC</given-names></name><name><surname>Andriantsitohaina</surname><given-names>R</given-names></name></person-group><article-title>Alteration by lipopolysaccharide of the relationship between intracellular calcium levels and contraction in rat mesenteric artery</article-title><source>Br J Pharmacol</source><year>1996</year><volume>118</volume><issue>5</issue><fpage>1218</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1996.tb15526.x</pub-id><?supplied-pmid 8818346?><pub-id pub-id-type="pmid">8818346</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Song SK, Karl IE, Ackerman JJ, Hotchkiss RS (1993) Increased intracellular Ca<sup>2+</sup>: a critical link in the pathophysiology of sepsis? Proc Natl Acad Sci U S A 90(9):3933&#8211;3937</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name><name><surname>Payen</surname><given-names>D</given-names></name></person-group><article-title>Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>3</issue><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70001-X</pub-id><?supplied-pmid 23427891?><pub-id pub-id-type="pmid">23427891</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>VM</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Barie</surname><given-names>PS</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Douglas</surname><given-names>IS</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Gardlund</surname><given-names>B</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Payen</surname><given-names>D</given-names></name><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Al-Khalidi</surname><given-names>HR</given-names></name><name><surname>Thompson</surname><given-names>V</given-names></name><name><surname>Janes</surname><given-names>J</given-names></name><name><surname>Macias</surname><given-names>WL</given-names></name><name><surname>Vangerow</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>MD</given-names></name></person-group><article-title>Drotrecogin alfa (activated) in adults with septic shock</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>22</issue><fpage>2055</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1202290</pub-id><?supplied-pmid 22616830?><pub-id pub-id-type="pmid">22616830</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>MR</given-names></name><name><surname>Roberts</surname><given-names>RE</given-names></name><name><surname>Gardiner</surname><given-names>SM</given-names></name><name><surname>Ralevic</surname><given-names>V</given-names></name></person-group><article-title>Effects of in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentery, kidney, and aorta</article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>306</volume><issue>2</issue><fpage>538</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.051805</pub-id><?supplied-pmid 12730359?><pub-id pub-id-type="pmid">12730359</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>T</given-names></name><name><surname>Mahajan</surname><given-names>RP</given-names></name><name><surname>March</surname><given-names>JE</given-names></name><name><surname>Kemp</surname><given-names>PA</given-names></name><name><surname>Gardiner</surname><given-names>SM</given-names></name></person-group><article-title>Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats</article-title><source>Br J Anaesth</source><year>2004</year><volume>93</volume><issue>3</issue><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1093/bja/aeh214</pub-id><?supplied-pmid 15220167?><pub-id pub-id-type="pmid">15220167</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarido</surname><given-names>KL</given-names></name><name><surname>Goncalves</surname><given-names>RP</given-names></name><name><surname>Junior</surname><given-names>AG</given-names></name><name><surname>da Silva-Santos</surname><given-names>JE</given-names></name></person-group><article-title>Increased activation of the Rho-A/Rho-kinase pathway in the renal vascular system is responsible for the enhanced reactivity to exogenous vasopressin in endotoxemic rats</article-title><source>Crit Care Med</source><year>2014</year><volume>42</volume><issue>6</issue><fpage>e461</fpage><lpage>e471</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000000313</pub-id><?supplied-pmid 24690572?><pub-id pub-id-type="pmid">24690572</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>SS</given-names></name></person-group><article-title>Regulation of blood flow in the microcirculation</article-title><source>Microcirculation</source><year>2005</year><volume>12</volume><issue>1</issue><fpage>33</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1080/10739680590895028</pub-id><?supplied-pmid 15804972?><pub-id pub-id-type="pmid">15804972</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Somlyo AP, Somlyo AV (2003) Ca<sup>2+</sup> sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83(4):1325&#8211;1358</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>De Backer</surname><given-names>D</given-names></name></person-group><article-title>Microvascular dysfunction as a cause of organ dysfunction in severe sepsis</article-title><source>Crit Care</source><year>2005</year><volume>9</volume><issue>Suppl 4</issue><fpage>S9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/cc3748</pub-id><?supplied-pmid 16168075?><pub-id pub-id-type="pmid">16168075</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Huber-Lang</surname><given-names>MS</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>Immunodesign of experimental sepsis by cecal ligation and puncture</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.214</pub-id><?supplied-pmid 19131954?><pub-id pub-id-type="pmid">19131954</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Leelahavanichkul</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>PS</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name></person-group><article-title>Animal models of sepsis and sepsis-induced kidney injury</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>10</issue><fpage>2868</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1172/JCI39421</pub-id><?supplied-pmid 19805915?><pub-id pub-id-type="pmid">19805915</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buras</surname><given-names>JA</given-names></name><name><surname>Holzmann</surname><given-names>B</given-names></name><name><surname>Sitkovsky</surname><given-names>M</given-names></name></person-group><article-title>Animal models of sepsis: setting the stage</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><issue>10</issue><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1038/nrd1854</pub-id><?supplied-pmid 16224456?><pub-id pub-id-type="pmid">16224456</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>WJ</given-names></name><name><surname>Choudhry</surname><given-names>M</given-names></name><name><surname>Schwacha</surname><given-names>MG</given-names></name><name><surname>Kerby</surname><given-names>JD</given-names></name><name><surname>Rue</surname><given-names>LW</given-names><suffix>3rd</suffix></name><name><surname>Bland</surname><given-names>KI</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name></person-group><article-title>Cecal ligation and puncture</article-title><source>Shock</source><year>2005</year><volume>24</volume><issue>Suppl 1</issue><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000191414.94461.7e</pub-id><?supplied-pmid 16374373?><pub-id pub-id-type="pmid">16374373</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Deane AM, Rayner CK, Keeshan A, Cvijanovic N, Marino Z, Nguyen NQ, Chia B, Summers MJ, Sim JA, van Beek T, Chapman MJ, Horowitz M, Young RL (2013) The effects of critical illness on intestinal glucose sensing, transporters, and absorption. Crit Care Med.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Deyo</surname><given-names>DJ</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name><name><surname>Johnston</surname><given-names>WE</given-names></name><name><surname>Sherwood</surname><given-names>ER</given-names></name></person-group><article-title>Hemodynamic and cardiac contractile function during sepsis caused by cecal ligation and puncture in mice</article-title><source>Shock</source><year>2004</year><volume>21</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000101673.49265.5d</pub-id><?supplied-pmid 14676681?><pub-id pub-id-type="pmid">14676681</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Sandt</surname><given-names>AM</given-names></name><name><surname>Windler</surname><given-names>R</given-names></name><name><surname>Godecke</surname><given-names>A</given-names></name><name><surname>Ohlig</surname><given-names>J</given-names></name><name><surname>Zander</surname><given-names>S</given-names></name><name><surname>Reinartz</surname><given-names>M</given-names></name><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>van Faassen</surname><given-names>EE</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name><name><surname>Schrader</surname><given-names>J</given-names></name><name><surname>Kelm</surname><given-names>M</given-names></name><name><surname>Merx</surname><given-names>MW</given-names></name></person-group><article-title>Endothelial NOS (NOS3) impairs myocardial function in developing sepsis</article-title><source>Basic Res Cardiol</source><year>2013</year><volume>108</volume><issue>2</issue><fpage>330</fpage><pub-id pub-id-type="doi">10.1007/s00395-013-0330-8</pub-id><?supplied-pmid 23397596?><pub-id pub-id-type="pmid">23397596</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Dumasius</surname><given-names>A</given-names></name><name><surname>Easington</surname><given-names>C</given-names></name><name><surname>Colilla</surname><given-names>SA</given-names></name><name><surname>Neumann</surname><given-names>A</given-names></name><name><surname>Parrillo</surname><given-names>JE</given-names></name></person-group><article-title>Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><issue>5</issue><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.164.5.2010073</pub-id><?supplied-pmid 11549551?><pub-id pub-id-type="pmid">11549551</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>J</given-names></name><name><surname>Muriel-Bombin</surname><given-names>A</given-names></name><name><surname>Sagredo</surname><given-names>V</given-names></name><name><surname>Taboada</surname><given-names>F</given-names></name><name><surname>Gandia</surname><given-names>F</given-names></name><name><surname>Tamayo</surname><given-names>L</given-names></name><name><surname>Collado</surname><given-names>J</given-names></name><name><surname>Garcia-Labattut</surname><given-names>A</given-names></name><name><surname>Carriedo</surname><given-names>D</given-names></name><name><surname>Valledor</surname><given-names>M</given-names></name><name><surname>De Frutos</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>MJ</given-names></name><name><surname>Caballero</surname><given-names>A</given-names></name><name><surname>Guerra</surname><given-names>J</given-names></name><name><surname>Alvarez</surname><given-names>B</given-names></name><name><surname>Mayo</surname><given-names>A</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name></person-group><article-title>Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study</article-title><source>Crit Care</source><year>2008</year><volume>12</volume><issue>6</issue><fpage>R158</fpage><pub-id pub-id-type="doi">10.1186/cc7157</pub-id><?supplied-pmid 19091069?><pub-id pub-id-type="pmid">19091069</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaukonen</surname><given-names>KM</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Pilcher</surname><given-names>D</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012</article-title><source>JAMA</source><year>2014</year><volume>311</volume><issue>13</issue><fpage>1308</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.2637</pub-id><?supplied-pmid 24638143?><pub-id pub-id-type="pmid">24638143</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MP</given-names></name><name><surname>Susnjar</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Sutherland</surname><given-names>C</given-names></name><name><surname>Kiss</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>DP</given-names></name></person-group><article-title>Phosphorylation of the protein phosphatase type 1 inhibitor protein CPI-17 by protein kinase C</article-title><source>Methods Mol Biol</source><year>2007</year><volume>365</volume><fpage>209</fpage><lpage>223</lpage><?supplied-pmid 17200564?><pub-id pub-id-type="pmid">17200564</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>JF</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Clapp</surname><given-names>LH</given-names></name></person-group><article-title>Role of KATP channels in sepsis</article-title><source>Cardiovasc Res</source><year>2006</year><volume>72</volume><issue>2</issue><fpage>220</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2006.07.011</pub-id><?supplied-pmid 16963005?><pub-id pub-id-type="pmid">16963005</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog</article-title><source>J Clin Invest</source><year>1992</year><volume>89</volume><issue>6</issue><fpage>2071</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.1172/JCI115820</pub-id><?supplied-pmid 1602014?><pub-id pub-id-type="pmid">1602014</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carcillo</surname><given-names>JA</given-names></name><name><surname>Litten</surname><given-names>RZ</given-names></name><name><surname>Suba</surname><given-names>EA</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><article-title>Alterations in rat aortic alpha 1-adrenoceptors and alpha 1-adrenergic stimulated phosphoinositide hydrolysis in intraperitoneal sepsis</article-title><source>Circ Shock</source><year>1988</year><volume>26</volume><issue>3</issue><fpage>331</fpage><lpage>339</lpage><?supplied-pmid 2850119?><pub-id pub-id-type="pmid">2850119</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Awady</surname><given-names>MS</given-names></name><name><surname>Smirnov</surname><given-names>SV</given-names></name><name><surname>Watson</surname><given-names>ML</given-names></name></person-group><article-title>Voltage-independent calcium channels mediate lipopolysaccharide-induced hyporeactivity to endothelin-1 in the rat aorta</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2009</year><volume>296</volume><issue>5</issue><fpage>H1408</fpage><lpage>H1415</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01305.2008</pub-id><?supplied-pmid 19286939?><pub-id pub-id-type="pmid">19286939</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'Alessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>Vasopressin deficiency contributes to the vasodilation of septic shock</article-title><source>Circulation</source><year>1997</year><volume>95</volume><issue>5</issue><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.95.5.1122</pub-id><?supplied-pmid 9054839?><pub-id pub-id-type="pmid">9054839</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Maxime</surname><given-names>V</given-names></name><name><surname>Ibrahim</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>JC</given-names></name><name><surname>Abe</surname><given-names>E</given-names></name><name><surname>Boudou</surname><given-names>P</given-names></name></person-group><article-title>Diagnosis of adrenal insufficiency in severe sepsis and septic shock</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><issue>12</issue><fpage>1319</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1164/rccm.200509-1369OC</pub-id><?supplied-pmid 16973979?><pub-id pub-id-type="pmid">16973979</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name><name><surname>Cunnion</surname><given-names>RE</given-names></name><name><surname>Zimmerberg</surname><given-names>J</given-names></name></person-group><article-title>Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats</article-title><source>Am J Physiol</source><year>1993</year><volume>264</volume><issue>2 Pt 2</issue><fpage>H660</fpage><lpage>H663</lpage><?supplied-pmid 7680541?><pub-id pub-id-type="pmid">7680541</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracey</surname><given-names>KJ</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Lowry</surname><given-names>SF</given-names></name><name><surname>Merryweather</surname><given-names>J</given-names></name><name><surname>Wolpe</surname><given-names>S</given-names></name><name><surname>Milsark</surname><given-names>IW</given-names></name><name><surname>Hariri</surname><given-names>RJ</given-names></name><name><surname>Fahey</surname><given-names>TJ</given-names><suffix>3rd</suffix></name><name><surname>Zentella</surname><given-names>A</given-names></name><name><surname>Albert</surname><given-names>JD</given-names></name></person-group><article-title>Shock and tissue injury induced by recombinant human cachectin</article-title><source>Science</source><year>1986</year><volume>234</volume><issue>4775</issue><fpage>470</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1126/science.3764421</pub-id><?supplied-pmid 3764421?><pub-id pub-id-type="pmid">3764421</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>The pathogenesis of vasodilatory shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>8</issue><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1056/NEJMra002709</pub-id><?supplied-pmid 11529214?><pub-id pub-id-type="pmid">11529214</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernow</surname><given-names>B</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><article-title>Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches</article-title><source>Circ Shock</source><year>1986</year><volume>18</volume><issue>2</issue><fpage>141</fpage><lpage>155</lpage><?supplied-pmid 3004777?><pub-id pub-id-type="pmid">3004777</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>SM</given-names></name></person-group><article-title>Vasoactive drugs in circulatory shock</article-title><source>Am J Respir Crit Care Med</source><year>2011</year><volume>183</volume><issue>7</issue><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1164/rccm.201006-0972CI</pub-id><?supplied-pmid 21097695?><pub-id pub-id-type="pmid">21097695</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Fitridge</surname><given-names>RTM</given-names></name></person-group><article-title>Vascular smooth muscle structure and function</article-title><source>Mechanisms of vascular disease</source><year>2011</year><publisher-loc>Adelaide</publisher-loc><publisher-name>University of Adelaide Press</publisher-name></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichterman</surname><given-names>KA</given-names></name><name><surname>Baue</surname><given-names>AE</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name></person-group><article-title>Sepsis and septic shock&#8212;a review of laboratory models and a proposal</article-title><source>J Surg Res</source><year>1980</year><volume>29</volume><issue>2</issue><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/0022-4804(80)90037-2</pub-id><?supplied-pmid 6997619?><pub-id pub-id-type="pmid">6997619</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejager</surname><given-names>L</given-names></name><name><surname>Pinheiro</surname><given-names>I</given-names></name><name><surname>Dejonckheere</surname><given-names>E</given-names></name><name><surname>Libert</surname><given-names>C</given-names></name></person-group><article-title>Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?</article-title><source>Trends Microbiol</source><year>2011</year><volume>19</volume><issue>4</issue><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2011.01.001</pub-id><?supplied-pmid 21296575?><pub-id pub-id-type="pmid">21296575</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucher</surname><given-names>M</given-names></name><name><surname>Kees</surname><given-names>F</given-names></name><name><surname>Taeger</surname><given-names>K</given-names></name><name><surname>Kurtz</surname><given-names>A</given-names></name></person-group><article-title>Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>2</issue><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000048621.36569.69</pub-id><?supplied-pmid 12576967?><pub-id pub-id-type="pmid">12576967</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujihara</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>LA</given-names></name><name><surname>Gong</surname><given-names>MC</given-names></name><name><surname>Lemichez</surname><given-names>E</given-names></name><name><surname>Boquet</surname><given-names>P</given-names></name><name><surname>Somlyo</surname><given-names>AV</given-names></name><name><surname>Somlyo</surname><given-names>AP</given-names></name></person-group><article-title>Inhibition of RhoA translocation and calcium sensitization by in vivo ADP-ribosylation with the chimeric toxin DC3B</article-title><source>Mol Biol Cell</source><year>1997</year><volume>8</volume><issue>12</issue><fpage>2437</fpage><lpage>2447</lpage><pub-id pub-id-type="doi">10.1091/mbc.8.12.2437</pub-id><?supplied-pmid 9398666?><pub-id pub-id-type="pmid">9398666</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorg</surname><given-names>I</given-names></name><name><surname>Goehring</surname><given-names>UM</given-names></name><name><surname>Aktories</surname><given-names>K</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Recombinant Yersinia YopT leads to uncoupling of RhoA-effector interaction</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><issue>12</issue><fpage>7535</fpage><lpage>7543</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.12.7535-7543.2001</pub-id><?supplied-pmid 11705930?><pub-id pub-id-type="pmid">11705930</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucius</surname><given-names>C</given-names></name><name><surname>Arner</surname><given-names>A</given-names></name><name><surname>Steusloff</surname><given-names>A</given-names></name><name><surname>Troschka</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Aktories</surname><given-names>K</given-names></name><name><surname>Pfitzer</surname><given-names>G</given-names></name></person-group><article-title>Clostridium difficile toxin B inhibits carbachol-induced force and myosin light chain phosphorylation in guinea-pig smooth muscle: role of Rho proteins</article-title><source>J Physiol</source><year>1998</year><volume>506</volume><issue>Pt 1</issue><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.1998.083bx.x</pub-id><?supplied-pmid 9481674?><pub-id pub-id-type="pmid">9481674</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soong</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>TS</given-names></name><name><surname>Ahn</surname><given-names>DS</given-names></name><name><surname>Prince</surname><given-names>A</given-names></name></person-group><article-title>Staphylococcus aureus protein A mediates invasion across airway epithelial cells through activation of RhoA GTPase signaling and proteolytic activity</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>41</issue><fpage>35891</fpage><lpage>35898</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.295386</pub-id><?supplied-pmid 21878647?><pub-id pub-id-type="pmid">21878647</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boquet</surname><given-names>P</given-names></name></person-group><article-title>The cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli</article-title><source>Toxicon</source><year>2001</year><volume>39</volume><issue>11</issue><fpage>1673</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(01)00154-4</pub-id><?supplied-pmid 11595630?><pub-id pub-id-type="pmid">11595630</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>McKenzie</surname><given-names>G</given-names></name><name><surname>Witting</surname><given-names>PK</given-names></name><name><surname>Stasch</surname><given-names>JP</given-names></name><name><surname>Hahn</surname><given-names>M</given-names></name><name><surname>Changsirivathanathamrong</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>BJ</given-names></name><name><surname>Ball</surname><given-names>HJ</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Mellor</surname><given-names>AL</given-names></name><name><surname>Keaney</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Hunt</surname><given-names>NH</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name></person-group><article-title>Kynurenine is an endothelium-derived relaxing factor produced during inflammation</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1038/nm.2092</pub-id><?supplied-pmid 20190767?><pub-id pub-id-type="pmid">20190767</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitazawa</surname><given-names>T</given-names></name><name><surname>Semba</surname><given-names>S</given-names></name><name><surname>Huh</surname><given-names>YH</given-names></name><name><surname>Kitazawa</surname><given-names>K</given-names></name><name><surname>Eto</surname><given-names>M</given-names></name></person-group><article-title>Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1</article-title><source>J Physiol</source><year>2009</year><volume>587</volume><issue>Pt 14</issue><fpage>3587</fpage><lpage>3603</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2009.172189</pub-id><?supplied-pmid 19470783?><pub-id pub-id-type="pmid">19470783</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surks</surname><given-names>HK</given-names></name><name><surname>Mochizuki</surname><given-names>N</given-names></name><name><surname>Kasai</surname><given-names>Y</given-names></name><name><surname>Georgescu</surname><given-names>SP</given-names></name><name><surname>Tang</surname><given-names>KM</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Lincoln</surname><given-names>TM</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name></person-group><article-title>Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha</article-title><source>Science</source><year>1999</year><volume>286</volume><issue>5444</issue><fpage>1583</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1126/science.286.5444.1583</pub-id><?supplied-pmid 10567269?><pub-id pub-id-type="pmid">10567269</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakr</surname><given-names>Y</given-names></name><name><surname>Dubois</surname><given-names>MJ</given-names></name><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Creteur</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><issue>9</issue><fpage>1825</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000138558.16257.3F</pub-id><?supplied-pmid 15343008?><pub-id pub-id-type="pmid">15343008</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>G</given-names></name><name><surname>Regueira</surname><given-names>T</given-names></name><name><surname>Bruhn</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>Rovegno</surname><given-names>M</given-names></name><name><surname>Fuentealba</surname><given-names>A</given-names></name><name><surname>Veas</surname><given-names>E</given-names></name><name><surname>Berrutti</surname><given-names>D</given-names></name><name><surname>Florez</surname><given-names>J</given-names></name><name><surname>Kattan</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Ince</surname><given-names>C</given-names></name></person-group><article-title>Relationship of systemic, hepatosplanchnic, and microcirculatory perfusion parameters with 6-hour lactate clearance in hyperdynamic septic shock patients: an acute, clinical-physiological, pilot study</article-title><source>Ann Intensive Care</source><year>2012</year><volume>2</volume><issue>1</issue><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/2110-5820-2-44</pub-id><?supplied-pmid 23067578?><pub-id pub-id-type="pmid">23067578</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>MD</given-names></name><name><surname>Donnino</surname><given-names>M</given-names></name><name><surname>Clardy</surname><given-names>P</given-names></name><name><surname>Talmor</surname><given-names>D</given-names></name><name><surname>Shapiro</surname><given-names>NI</given-names></name></person-group><article-title>Occult hypoperfusion and mortality in patients with suspected infection</article-title><source>Intensive Care Med</source><year>2007</year><volume>33</volume><issue>11</issue><fpage>1892</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1007/s00134-007-0680-5</pub-id><?supplied-pmid 17618418?><pub-id pub-id-type="pmid">17618418</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>D</given-names></name><name><surname>Creteur</surname><given-names>J</given-names></name><name><surname>Dubois</surname><given-names>MJ</given-names></name><name><surname>Sakr</surname><given-names>Y</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Verdant</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><issue>2</issue><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000198107.61493.5A</pub-id><?supplied-pmid 16424721?><pub-id pub-id-type="pmid">16424721</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RJ</given-names></name><name><surname>Liao</surname><given-names>CX</given-names></name><name><surname>Chen</surname><given-names>DZ</given-names></name></person-group><article-title>Effect of tetramethylpyrazine on endothelin, von Willebrand factor and thromboxane A2 during cardiopulmonary bypass in patients of congenital heart disease with pulmonary hypertension</article-title><source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source><year>2003</year><volume>23</volume><issue>4</issue><fpage>268</fpage><lpage>271</lpage><?supplied-pmid 12764908?><pub-id pub-id-type="pmid">12764908</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>SS</given-names></name><name><surname>Duling</surname><given-names>BR</given-names></name></person-group><article-title>Flow control among microvessels coordinated by intercellular conduction</article-title><source>Science</source><year>1986</year><volume>234</volume><issue>4778</issue><fpage>868</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1126/science.3775368</pub-id><?supplied-pmid 3775368?><pub-id pub-id-type="pmid">3775368</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>DG</given-names></name><name><surname>Segal</surname><given-names>SS</given-names></name></person-group><article-title>Endothelial and smooth muscle cell conduction in arterioles controlling blood flow</article-title><source>Am J Physiol</source><year>1998</year><volume>274</volume><issue>1 Pt 2</issue><fpage>H178</fpage><lpage>H186</lpage><?supplied-pmid 9458866?><pub-id pub-id-type="pmid">9458866</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errasti</surname><given-names>AE</given-names></name><name><surname>Luciani</surname><given-names>LI</given-names></name><name><surname>Cesio</surname><given-names>CE</given-names></name><name><surname>Tramontano</surname><given-names>J</given-names></name><name><surname>Boveris</surname><given-names>D</given-names></name><name><surname>Daray</surname><given-names>FM</given-names></name><name><surname>Nowak</surname><given-names>W</given-names></name><name><surname>Pelorosso</surname><given-names>FG</given-names></name><name><surname>Rothlin</surname><given-names>RP</given-names></name></person-group><article-title>Potentiation of adrenaline vasoconstrictor response by sub-threshold concentrations of U-46619 in human umbilical vein: involvement of smooth muscle prostanoid TP(alpha) receptor isoform</article-title><source>Eur J Pharmacol</source><year>2007</year><volume>562</volume><issue>3</issue><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.01.085</pub-id><?supplied-pmid 17362923?><pub-id pub-id-type="pmid">17362923</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name></person-group><article-title>Severe sepsis and septic shock</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>9</issue><fpage>840</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1208623</pub-id><?supplied-pmid 23984731?><pub-id pub-id-type="pmid">23984731</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artenstein</surname><given-names>AW</given-names></name><name><surname>Higgins</surname><given-names>TL</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name></person-group><article-title>Sepsis and scientific revolutions</article-title><source>Crit Care Med</source><year>2013</year><volume>41</volume><issue>12</issue><fpage>2770</fpage><lpage>2772</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e31829eb98f</pub-id><?supplied-pmid 23989175?><pub-id pub-id-type="pmid">23989175</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essler</surname><given-names>M</given-names></name><name><surname>Amano</surname><given-names>M</given-names></name><name><surname>Kruse</surname><given-names>HJ</given-names></name><name><surname>Kaibuchi</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>PC</given-names></name><name><surname>Aepfelbacher</surname><given-names>M</given-names></name></person-group><article-title>Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>34</issue><fpage>21867</fpage><lpage>21874</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.34.21867</pub-id><?supplied-pmid 9705325?><pub-id pub-id-type="pmid">9705325</pub-id></element-citation></ref></ref-list></back></article>